Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer

 

DataScience.ir

Code: Article-7318

Title: Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer

لینک: http://ascopubs.org/doi/abs/10.1200/JCO.2017.76.2294?url_ver=Z39.88

Price: Free

Download Link:

Advanced anaplastic lymphoma kinase (ALK) fusion-positive non–small-cell lung cancers (NSCLCs) are effectively treated with ALK tyrosine kinase inhibitors (TKIs). However, clinical outcomes in these patients vary, and the benefit of TKIs is limited as a result of acquired resistance. Emerging data suggest that the ALK fusion variant may affect clinical outcome, but the molecular basis for this association is unknown.

 

Leave Comment

آدرس ایمیل شما منتشر نخواهد شد.